Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Controlled Study to Compare Straumann® VivOss™ to Geistlich Bio-Oss® in Sinus Floor Augmentation.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have voluntarily signed the informed consent before any study related action~* Males and females with at least 18 years of age (including 18 years)~* Subject needs augmentation procedure in the sinus to prepare for implant placement.~* Subject must have a residual bone height of 2 to 4 mm.~* Adequate oral hygiene ((Full mouth plaque index (O'Leary, et al. 1972 ) \<25%) at baseline~* Adequate control of inflammation ((full mouth bleeding on probing (Ainamo and Bay 1975)) ≤25% at baseline~Exclusion Criteria:~* Systemic disease that would interfere with bone or wound healing and dental implant therapy (e.g. uncontrolled diabetes)~* Systemic disease that would interfere with bone or wound healing and dental implant therapy (e.g. uncontrolled diabetes)~* Any contraindications for general bone grafting and oral surgical procedures~* Any anomalies of the sinus that could interfere with planned procedures~* History of local irradiation therapy~* Local inflammation, including untreated periodontitis~* Medical conditions requiring chronic high dose steroid therapy~* Treatment with an investigational drug or device within a 30 day period immediately prior to surgery at visit 2, or expected participation in any other investigational drug or device study during the conduct of this trial.~* Antibiotic treatment or anti-inflammatory treatment within 4 weeks prior to surgery~* History of alcoholism or drug abuse~* Immunocompromised subjects~* Subjects who smoke \>10 cigarettes per day or tobacco equivalents or chew tobacco~* Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance or unreliability~* Physical or mental disabilities that would interfere with the ability to perform adequate oral hygiene~* Current pregnancy (pregnancy test) and breastfeeding women~Secondary exclusion criterium:~Defects of the Schneider Membrane

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Straumann VivOss (Type: EXPERIMENTAL): Straumann® VivOss™Straumann® VivOss™, is a synthetic bone graft substitute in granulated form. It consists of \> 90% TCP (Tri-Calcium-Phosphate -Ca3(PO4)2) and \< 10% Hydroxyapatite (Ca10(PO4)6 (OH)2). The granules have a size of 250-1000 μm.
- Geistlich Bio-Oss (Type: ACTIVE_COMPARATOR): The control device is Geistlich Bio-Oss® spongiosa granules (Geistlich Pharma AG, Wolhusen, Switzerland), 0.25-1 mm in diameter. It's a natural bone mineral of bovine origin. It shall be used according to the instructions of the manufacturer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete